Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Cellular Immunology|May 10, 2025
Characterization of lysate from NK-92 cells and its potential use as an immunotherapeutic modalityHimani Chinnapen, Laurent Boissel, Courtney Fleenor, et al.
Oncoimmunology|January 10, 2014
Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicityLaurent Boissel, Monica Betancur-Boissel, Weiquan Lu, et al.
Transfusion|May 12, 2012
Successful "in-flight" activation of natural killer cells during long-distance shippingScott A Koepsell, Diane M Kadidlo, Susan Fautsch, et al.
Cytotherapy|November 27, 2016
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphomaSarah Oelsner, Miriam E Friede, Congcong Zhang, et al.
Transfusion|June 29, 2012
Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusionsHans Klingemann, Carrie Grodman, Elliott Cutler, et al.
Oncotarget|November 19, 2016
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 alleleCaroline Jochems, James W Hodge, Massimo Fantini, et al.
Journal for Immunotherapy of Cancer|February 28, 2024
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulationJiri Eitler, Wiebke Rackwitz, Natalie Wotschel, et al.
Blood|February 26, 2004
Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantationNicolaus Kröger, Georgia Schilling, Hermann Einsele, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2004
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myelomaNicolaus Kröger, Jose A Perez-Simon, Han Myint, et al.
Pageof 3